title: Probable cytarabine-induced acral erythema: report of 2 pediatric cases.
abstract: Acral erythema (palmoplantar erythrodysesthesia) is a localized skin side effect that is seen most often in patients receiving cytarabine, liposomal pegylated doxorubicin, capecitabine, and 5-fluorouracil. It is characterized by painful erythema of both palms and soles with symmetrically well-defined borders, which may progress to bullae formation and desquamation. It is frequently occurred in patients with acute myeloid leukemia and lymphoma. Here, we reported 2 cases of acral erythema that developed during cytarabin-etoposide and cytarabine-mitoxantrone combination treatment for acute myeloid leukemia. Although rarely reported in children, pediatricians should especially be aware of this reaction when taking care of children who receive chemotherapy.
authors: Dr. Sami Ulus Research and Training Hospital of Women's and Children's Health and Diseases, Pediatric Allergy Department, Ankara, Turkey.
authors: Serap
authors: S
authors: Ozmen
authors: Mahmut
authors: M
authors: Dogru
authors: Ceyhun
authors: C
authors: Bozkurt
authors: Ayse Ceyda
authors: AC
authors: Kocaoglu
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D002675:Child, Preschool; D003561:Cytarabine / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D060831:Hand-Foot Syndrome / Q000175:diagnosis* / Q000188:drug therapy; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008942:Mitoxantrone / Q000008:administration & dosage; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*; D011379:Prognosis
chemical_list: D003561:Cytarabine; D005047:Etoposide; D008942:Mitoxantrone